Mechanistic Scientist · Antimicrobial & Biofilm Platforms

Edgar F. Ferrer-GonzálezPh.D.

Building translational platforms at the intersection of antimicrobial resistance, microbial systems, and infection-control innovation — from mechanism to deployment.

8+
Peer-Reviewed
Publications
1
Licensed US
Patent
3
Active Research
Platforms
Open
To Collaboration
& Consulting

Translating science into
strategic advantage

A cross-section of platforms built at the intersection of mechanistic rigor and real-world deployment.

This work represents an ongoing, industry-based platform designed to address biofilm persistence using non-corrosive, mechanism-aware strategies suitable for repeated use and consumer-facing environments. Rather than optimizing for maximal destruction, the platform focuses on controlled interference with biofilm formation, maturation, and maintenance—balancing efficacy, safety, and real-world usability.

I build analysis workflows that make complex microbiology interpretable and comparable across experiments, operators, and partners. The focus is not "pretty plots"—it's turning heterogeneous biological readouts into quality-controlled evidence that supports go/no-go decisions, mechanistic interpretation, and cross-functional alignment.

I build mechanism-first antibacterial platforms around the bacterial division machinery (FtsZ) to turn "synergy" into decision-grade evidence — connecting chemical tools, mechanistic experiments, and translational combination studies showing that FtsZ inhibition can potentiate β-lactams against MRSA.

Edgar F. Ferrer-González, Ph.D.
Ph.D. · Industry Scientist

Illuminating the invisible machinery of life to engineer better interventions.

I was drawn early to biomedical research and healthcare, guided by the realization that the greatest leverage lies not in treating symptoms, but in understanding and redesigning the systems that generate them. That systems-thinking lens, shaped by genetics and microbial physiology, has since defined my work at the intersection of antimicrobial resistance (AMR), host–microbe interactions, and experimental therapeutics.

I specialize in uncovering and operationalizing the mechanisms that govern microbial behavior. Early in my training, visualizing mCherry-tagged proteins inside living bacteria made something clear to me: seeing the mechanism is the first step toward controlling it. Since then, my work has focused on making invisible biological processes legible, measurable, and actionable — whether through molecular tools, assay platforms, or data-driven experimental models.

Today, I work as an industry scientist developing and scaling experimental systems that support antimicrobial, microbiome, and biofilm-focused innovation. I lead the design and execution of studies across internal labs and CRO partnerships, build regulatory-aligned assay platforms, and translate complex biological outputs into decision-grade evidence that informs pipeline strategy, product development, and claims substantiation.

A core throughline of my work is platform thinking: building tools, workflows, and models that outlive individual projects and enable faster, more confident decisions across teams. This includes co-inventing imaging technologies licensed by MilliporeSigma, establishing antimicrobial and anti-biofilm testing pipelines, and integrating experimental data with clear scientific narratives for cross-functional stakeholders.

I am driven by the challenge of antimicrobial resistance and by the belief that durable solutions emerge when scientific depth is paired with systems-level thinking and strong execution.

Leadership Style
Strategic Orchestration

I lead by establishing the technical "gold standards" in the lab, then empowering teams to execute within scalable frameworks that ensure scientific rigor and independence.

Scientific Mission
The Engine of Discovery

I don't just interpret data; I architect the experimental platforms and quantitative workflows that generate the high-fidelity evidence models cannot yet predict.

Peer-reviewed science &
licensed innovation

From discovery through patent to commercialization — research that moves the field forward.

2024
U.S. Patent 12,061,201 B2
Fluorescent probes for the visualization of FtsZ in Gram-positive and Gram-negative bacterial pathogens

Novel fluorescent probes designed to target the FtsZ protein for real-time visualization of division machinery. Licensed and commercialized via MilliporeSigma.

2025
Frontiers in Microbiology
Taxonomic and functional profiling of the vulvar microbiome indicates variations related to ecological signatures, aging, and health status

Characterization of the vulvar microbiome across different life stages, identifying specific ecological signatures and microbial variations that correlate with aging and overall health status.

2022
Medicinal Chemistry Research
Combination with a FtsZ inhibitor potentiates the in vivo efficacy of oxacillin against MRSA

Demonstrates how FtsZ inhibitors restore effectiveness of traditional antibiotics like oxacillin against MRSA strains.

2022
Medicinal Chemistry Research
Novel MreB inhibitors with antibacterial activity against Gram-negative bacteria

Identification of small molecules that inhibit MreB, targeting the bacterial cytoskeleton in Gram-negative pathogens.

2022
ACS Chemical Biology
Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor

Discovery of a new benzamide compound with superior bactericidal activity and in vivo efficacy against multidrug-resistant MRSA.

2021
Journal of Bacteriology
Impact of FtsZ inhibition on the localization of penicillin binding proteins in MRSA

Investigation of the spatial relationship between FtsZ and penicillin-binding proteins in MRSA cell wall synthesis.

2019
Scientific Reports
Structure-guided design of a fluorescent probe for the visualization of FtsZ

Structure-guided molecular design of versatile fluorescent probes for FtsZ protein across clinical pathogens.

2017
Antimicrobial Agents & Chemotherapy
β-Lactam antibiotics with high affinity for PBP2 act synergistically with FtsZ-targeting agent TXA707

Identifies beta-lactams with high PBP2 affinity that maximize synergy with FtsZ inhibitors against MRSA.

Ideas from the
bench & beyond

Insights on microbiology, scientific practice, and the systems that shape them.

Functional Mechanisms

Connecting to Functional Mechanisms…

Fetching latest insights from functionalmechanisms.blogspot.com…

Systems-level expertise
at scale

Platform ownership examples illustrating transferable, systems-level scientific leadership.

01 // Platform

AMR & Infection Control Platforms

Designing mechanistic and translational platforms to combat antimicrobial resistance by breaking persistence, transmission, and treatment failure across clinical and consumer environments.

02 // Systems

Biofilm & Microbial Systems

Understanding and disrupting microbial systems—biofilms, communities, and host–microbe interactions—to reduce chronic infection risk and improve intervention durability.

03 // Translation

Mechanistic Pharmacology

Translating molecular and cellular mechanisms into decision-grade evidence that informs therapeutic strategy, candidate selection, and resistance-mitigation approaches.

04 // Enablement

Scientific Platforms & Decision Enablement

Building scalable assay systems, analytics, and scientific narratives that turn complex biological data into confident decisions across R&D, regulatory, and product teams.